Question 1

Is Retatrutide approved anywhere?

Accepted Answer

Not by the FDA. Phase 3 results (TRIUMPH-1 and TRIUMPH-2) were published in 2026, but the drug has not been approved. The FDA has sent warning letters to sellers of retatrutide, calling it an unapproved new drug. Anything sold under its name now comes from unregulated grey-market or research-chemical suppliers.

Question 2

Why add glucagon agonism?

Accepted Answer

Glucagon raises blood glucose, which is a risk when it acts alone. In mouse studies of retatrutide, glucagon-receptor activity raised energy expenditure, and this added to the reduced food intake driven by GIP and GLP-1. In the human trials, glucose control improved rather than worsened, so the overall balance looked favourable. Long-term data are still limited.

Question 3

How does retatrutide compare to tirzepatide and semaglutide for weight loss?

Accepted Answer

In its own trials, retatrutide 12 mg produced a mean −24.2% at 48 weeks (phase 2) and −25.0% at 80 weeks (phase 3 TRIUMPH-1). No head-to-head trial against tirzepatide or semaglutide has been published. Comparing across trials is unreliable because the populations, durations and analysis methods differ.

Question 4

When is retatrutide expected to be FDA-approved?

Accepted Answer

There is no confirmed date. Phase 3 trials have now reported weight-loss results, but approval depends on a regulatory submission and on the FDA's review of efficacy and safety data. Until then, retatrutide is investigational.

Question 5

Does the glucagon component affect blood sugar negatively?

Accepted Answer

Not in the trials so far. In the phase 2 type 2 diabetes trial (Rosenstock et al., Lancet 2023), HbA1c fell by up to 2.02 percentage points at 24 weeks on the 12 mg escalation arm, compared with 1.41 points on dulaglutide 1.5 mg and essentially no change on placebo. No severe hypoglycaemia was reported. TRIUMPH-2 also found better glycaemic control in people with obesity and type 2 diabetes.

Question 6

Is retatrutide safe for people without diabetes?

Accepted Answer

The phase 2 obesity trial and the phase 3 TRIUMPH-1 trial enrolled adults without diabetes. The most common adverse events were gastrointestinal: dose-related and mostly mild to moderate in phase 2. Phase 2 also saw dose-dependent heart-rate increases that peaked at 24 weeks and then declined. These trials cover up to 80 weeks of treatment, so longer-term and rare risks are not yet known. The drug is not approved.

Question 7

Should I wait for retatrutide instead of starting tirzepatide?

Accepted Answer

Tirzepatide is approved and has an established clinical track record. Retatrutide is investigational and cannot be legally prescribed outside trials. Whether to start an approved treatment now is a decision for you and your clinician; waiting for an unapproved drug delays proven therapy.

Question 8

How does the triple receptor mechanism of retatrutide work at a molecular level?

Accepted Answer

Retatrutide is one peptide that activates three G-protein-coupled receptors: GIP-R, GLP-1R, and the glucagon receptor (GCGR). In vitro it has balanced GCGR and GLP-1R activity and more GIPR activity (Coskun et al., Cell Metabolism 2022). GLP-1R and GIPR agonism lower glucose and reduce calorie intake, and retatrutide delays gastric emptying. In obese mice, the GCGR component increased energy expenditure, adding to the weight loss from reduced intake. In human trials, glycaemic control improved despite the glucagon component.

Question 9

What were the detailed Phase 2 clinical trial results for retatrutide?

Accepted Answer

The phase 2 obesity trial (Jastreboff et al., NEJM 2023) randomized 338 adults to retatrutide 1, 4, 8 or 12 mg or placebo weekly for 48 weeks. Mean weight change at 48 weeks was −8.7% (1 mg), −17.1% (4 mg), −22.8% (8 mg) and −24.2% (12 mg), versus −2.1% with placebo. On 12 mg, 100%, 93% and 83% of participants lost at least 5%, 10% and 15% of body weight. The parallel type 2 diabetes trial (Rosenstock et al., Lancet 2023) found HbA1c reductions of up to 2.02 percentage points at 24 weeks and dose-dependent weight loss of up to about 17% at 36 weeks. In both trials, adverse events were mainly gastrointestinal: nausea, diarrhoea, vomiting and constipation.

Question 10

What is known about long-term safety of retatrutide?

Accepted Answer

The longest published trials are the 80-week phase 3 studies. In TRIUMPH-2, gastrointestinal events were most common. Hypotension and dysesthesia were more frequent with retatrutide than placebo. Permanent discontinuation due to adverse events or death was higher with 9 mg (12%) and 12 mg (8%) than with 4 mg or placebo. Phase 2 found dose-dependent heart-rate increases. Questions that still need longer and larger datasets include rare events such as pancreatitis and gallbladder disease, cardiovascular outcomes, and changes in lean mass and bone during major weight loss. Long-term risk is not yet fully known.

Question 11

Does retatrutide reduce liver fat, and could it treat NAFLD/NASH?

Accepted Answer

A substudy of the phase 2 obesity trial (Sanyal et al., Nature Medicine 2024) included 98 participants with metabolic dysfunction-associated steatotic liver disease and at least 10% liver fat. At 24 weeks, the mean relative reduction in liver fat was 81.4% with 8 mg and 82.4% with 12 mg, versus a 0.3% increase with placebo. Liver fat fell to normal levels (below 5%) in 79% and 86% of these participants. The reductions tracked changes in body weight, abdominal fat and insulin-sensitivity markers. This measured imaging-based liver fat, not liver histology, so it does not establish retatrutide as a treatment for steatohepatitis.

Question 12

What dose escalation schedule was used in retatrutide clinical trials?

Accepted Answer

In the phase 2 obesity trial, the 12 mg group started at 2 mg and was escalated. The 4 mg and 8 mg groups were randomized to start at either 2 mg or 4 mg. The lower 2 mg starting dose partly reduced gastrointestinal adverse events. The phase 3 TRIUMPH trials tested maintenance doses of 4, 9 and 12 mg weekly. These are trial protocols for an unapproved drug, not dosing guidance.

Question 13

How does retatrutide's triple agonism compare to dual GLP-1/glucagon agents like mazdutide?

Accepted Answer

Retatrutide activates GLP-1, GIP and glucagon receptors. Mazdutide and survodutide are GLP-1/glucagon dual agonists without the GIP component. No head-to-head trials between these agents have been published, so their relative efficacy and tolerability are unknown.

Question 14

Could retatrutide help with conditions beyond weight, such as sleep apnea or blood pressure?

Accepted Answer

TRIUMPH-1 tested two weight-related conditions. In 574 participants with knee osteoarthritis, retatrutide 9 mg and 12 mg reduced WOMAC pain more than placebo. In 243 participants with obstructive sleep apnea, the apnea-hypopnea index fell by about 22–34 events per hour, versus about 10 with placebo. Retatrutide is not approved for these or any other uses.

Question 15

How does retatrutide's triple agonism compare to amylin-based drugs like CagriSema?

Accepted Answer

They pursue large weight loss through different biology. Retatrutide is a single-molecule GIP/GLP-1/glucagon agonist. CagriSema combines a GLP-1 agonist (semaglutide) with an amylin analogue (cagrilintide). In their own phase 3 trials in adults without diabetes, CagriSema produced a mean −20.4% at 68 weeks (REDEFINE 1) and retatrutide 12 mg −25.0% at 80 weeks (TRIUMPH-1). The trials differed in length and design, and there is no head-to-head comparison. Neither drug is FDA-approved.

Origin / Manufacturer	Synthetic
Regulatory Status	Phase 3 investigational (no approvals as of 2026)
Active Components	Retatrutide (investigational)
Storage	Refrigerate 2–8°C (clinical supply)
Form Factor	Investigational subcutaneous injectable

Retatrutide

Specifications

Frequently Asked Questions

Sources & References

Related Peptides

Semaglutide

Tirzepatide